Wikidata entity: Q205517
C₂₁H₂₁ClN₄OS (P274)
Quantities
| P4250 | defined daily dose | 40 |
| P4250 | defined daily dose | 80 |
| P2067 | mass | 412.11246 |
| P3780 | active ingredient in | ... | Q47522349 (Geodon) | Geodon |
| P233 | canonical SMILES | String | C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54 | ??? |
| P373 | Commons category | String | Ziprasidone | ??? |
| P527 | has part(s) | ... | Q629 (oxygen) | oxygen |
| P527 | has part(s) | ... | Q623 (carbon) | carbon |
| P527 | has part(s) | ... | Q627 (nitrogen) | nitrogen |
| P527 | has part(s) | ... | Q682 (sulfur) | sulfur |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P3493 | legal status (medicine) | ... | Q879952 (boxed warning) | boxed warning |
| P2175 | medical condition treated | ... | Q41112 (schizophrenia) | schizophrenia |
| P2175 | medical condition treated | ... | Q170082 (psychosis) | psychosis |
| P2175 | medical condition treated | ... | Q154430 (anxiety) | anxiety |
| P2175 | medical condition treated | ... | Q191779 (Tourette syndrome) | Tourette syndrome |
| P2175 | medical condition treated | ... | Q834047 (schizoaffective disorder) | schizoaffective disorder |
| P361 | part of | ... | Q22274453 (response to ziprasidone) | response to ziprasidone |
| P129 | physically interacts with | ... | Q288797 (5-hydroxytryptamine receptor 1B) | 5-hydroxytryptamine receptor 1B |
| P129 | physically interacts with | ... | Q309513 (Histamine receptor H1) | Histamine receptor H1 |
| P129 | physically interacts with | ... | Q410142 (solute carrier family 6 member 4) | solute carrier family 6 member 4 |
| P129 | physically interacts with | ... | Q1949517 (5-hydroxytryptamine receptor 2A) | 5-hydroxytryptamine receptor 2A |
| P129 | physically interacts with | ... | Q2034004 (Dopamine receptor D2) | Dopamine receptor D2 |
| P129 | physically interacts with | ... | Q21108118 (5-hydroxytryptamine receptor 2C) | 5-hydroxytryptamine receptor 2C |
| P129 | physically interacts with | ... | Q21109355 (5-hydroxytryptamine receptor 7) | 5-hydroxytryptamine receptor 7 |
| P129 | physically interacts with | ... | Q21115043 (5-hydroxytryptamine receptor 1A) | 5-hydroxytryptamine receptor 1A |
| P129 | physically interacts with | ... | Q21115046 (5-hydroxytryptamine receptor 1D) | 5-hydroxytryptamine receptor 1D |
| P129 | physically interacts with | ... | Q21115051 (5-hydroxytryptamine receptor 1E) | 5-hydroxytryptamine receptor 1E |
| P3489 | pregnancy category | ... | Q3679234 (Australian pregnancy category B3) | Australian pregnancy category B3 |
| P3489 | pregnancy category | ... | Q28123617 (US pregnancy category C) | US pregnancy category C |
| P279 | subclass of | ... | Q193430 (heterocyclic compound) | heterocyclic compound |
| P2868 | subject has role | ... | Q1328275 (H1 antagonist) | H1 antagonist |
| P2868 | subject has role | ... | Q1927838 (alpha blocker) | alpha blocker |
| P2868 | subject has role | ... | Q208144 (antipsychotics) | antipsychotics |
| P2868 | subject has role | ... | Q3271533 (dopamine antagonist) | dopamine antagonist |
| P2868 | subject has role | ... | Q7455047 (serotonin antagonist) | serotonin antagonist |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | ziprasidone | ??? |
Why not click here or view trends?
log id: 2826531